Dapoxetine proves effective in clinical trial

ALZA's dapoxetine demonstrated its safety and efficacy in a new clinical trial. Researchers at the University of Minnesota concluded that the study of 2,600 men increased the average duration of intercourse from less than a minute to three minutes and 19 seconds. If the drug is eventually approved, it would be the first therapy on the market specifically for PE and likely to enjoy a large market. Dapoxetine is an SSRI drug, a category that is typically used to treat depression. This particular formulation, though, was designed specifically to treat PE, a condition that affects about a third of all men. The data from the study is outlined in an article in The Lancet.

- here's the BBC's report on dapoxetine